Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.00
-0.05 (-0.16%)
Mar 24, 2026, 1:34 PM CST
Market Cap1.33B -27.4%
Revenue (ttm)1.78M +189.6%
Net Income-87.75M
EPS-2.03
Shares Out42.95M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume69,017
Average Volume204,912
Open31.05
Previous Close31.05
Day's Range30.75 - 31.80
52-Week Range29.50 - 57.00
Beta-0.05
RSI37.71
Earnings DateMar 27, 2026

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. The company develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 15
Stock Exchange Taipei Exchange
Ticker Symbol 7427
Full Company Profile

Financial Performance

In 2024, TPEX:7427's revenue was 1.69 million, a decrease of -65.26% compared to the previous year's 4.85 million. Losses were -104.92 million, 72.0% more than in 2023.

Financial Statements